One Main Street
14th Floor
Cambridge, MA 02142
United States
617 252 0848
https://www.blackdiamondtherapeutics.com
Sector(s): Healthcare
Industry: Biotechnology
Full-time employees: 54
Name | Title | Pay | Exercised | Year born |
---|---|---|---|---|
Dr. Mark A. Velleca M.D., Ph.D. | CEO, President & Chairman | 43.89k | N/A | 1964 |
Dr. David M. Epstein Ph.D. | Co-Founder & Director | 885.08k | N/A | 1959 |
Dr. Fang Ni Pharm.D. | CFO, Principal Financial Officer and Chief Business Officer | 656.33k | N/A | 1987 |
Mr. Brent Hatzis-Schoch Esq., J.D. | COO & General Counsel | 683.29k | N/A | 1965 |
Dr. Elizabeth Buck Ph.D. | Co-Founder & Chief Scientific Officer | 340.47k | N/A | 1975 |
Ms. Erika Jones | VP of Finance, Corporate Controller & Principal Accounting Officer | N/A | N/A | 1985 |
Ms. Elizabeth L. Montgomery | Chief People Officer | N/A | N/A | 1972 |
Dr. Sergey Yurasov M.D., Ph.D. | Chief Medical Officer | N/A | N/A | 1969 |
Ms. Melanie Morrison | Chief Development Officer | N/A | N/A | N/A |
Black Diamond Therapeutics, Inc., a clinical-stage precision oncology medicine company, focuses on the discovery and development of therapies for patients with genetically defined cancers. The company's lead product candidate, BDTX-1535, a brain-penetrant, mutant selective, irreversible EGFR MasterKey inhibitor, designed to inhibit a family of oncogenic mutations, currently under Phase 1 clinical trial. It also develops BDTX-4933, a brain penetrant RAF MasterKey inhibitor, designed to be a brain penetrant and highly selective and potent inhibitor of oncogenic BRAF Class I, II, III and active RAF dimers, expected to initiate Phase 1 clinical trial. The company was formerly known as ASET Therapeutics, Inc. and changed its name to Black Diamond Therapeutics, Inc. in January 2018. Black Diamond Therapeutics, Inc. was incorporated in 2014 and is headquartered in Cambridge, Massachusetts.
Black Diamond Therapeutics, Inc.’s ISS governance QualityScore as of 1 March 2024 is 9. The pillar scores are Audit: 8; Board: 10; Shareholder rights: 8; Compensation: 7.